BidaskClub cut shares of CONMED Corporation (NASDAQ:CNMD) from a hold rating to a sell rating in a research report released on Thursday morning.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC lifted their price target on shares of CONMED Corporation from $48.00 to $54.00 and gave the stock a buy rating in a research note on Thursday, April 27th. Zacks Investment Research upgraded shares of CONMED Corporation from a sell rating to a hold rating in a report on Friday, April 28th. Finally, Ladenburg Thalmann Financial Services lowered shares of CONMED Corporation from a buy rating to a neutral rating and decreased their price objective for the company from $50.00 to $48.00 in a report on Thursday, April 27th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. CONMED Corporation has an average rating of Hold and an average price target of $49.33.

Shares of CONMED Corporation (CNMD) traded up 0.20% during trading on Thursday, hitting $51.26. 63,903 shares of the stock traded hands. The stock has a market cap of $1.43 billion, a PE ratio of 91.70 and a beta of 0.67. CONMED Corporation has a 12 month low of $37.60 and a 12 month high of $52.82. The firm’s 50-day moving average price is $50.87 and its 200-day moving average price is $46.91.

CONMED Corporation (NASDAQ:CNMD) last released its quarterly earnings results on Wednesday, July 26th. The medical technology company reported $0.41 EPS for the quarter, hitting analysts’ consensus estimates of $0.41. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The firm had revenue of $197.20 million during the quarter, compared to analysts’ expectations of $194.50 million. During the same period in the previous year, the company earned $0.47 EPS. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. Analysts anticipate that CONMED Corporation will post $1.86 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades CONMED Corporation (NASDAQ:CNMD) to Sell” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-conmed-corporation-nasdaqcnmd-to-sell/1464482.html.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 5th. Investors of record on Thursday, June 15th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, June 13th. This represents a $0.80 dividend on an annualized basis and a yield of 1.56%. CONMED Corporation’s payout ratio is 142.86%.

In related news, Director Dirk Kuyper sold 1,000 shares of CONMED Corporation stock in a transaction dated Tuesday, June 13th. The shares were sold at an average price of $52.24, for a total transaction of $52,240.00. Following the completion of the sale, the director now owns 10,739 shares in the company, valued at approximately $561,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Jonas sold 3,000 shares of CONMED Corporation stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $51.22, for a total transaction of $153,660.00. Following the sale, the executive vice president now owns 14,455 shares of the company’s stock, valued at approximately $740,385.10. The disclosure for this sale can be found here. Company insiders own 2.62% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in CONMED Corporation by 46,036.5% in the first quarter. BlackRock Inc. now owns 3,153,427 shares of the medical technology company’s stock valued at $140,043,000 after buying an additional 3,146,592 shares in the last quarter. Victory Capital Management Inc. raised its stake in CONMED Corporation by 12.9% in the first quarter. Victory Capital Management Inc. now owns 2,150,886 shares of the medical technology company’s stock valued at $95,521,000 after buying an additional 245,246 shares in the last quarter. Champlain Investment Partners LLC raised its stake in CONMED Corporation by 16.4% in the first quarter. Champlain Investment Partners LLC now owns 1,728,445 shares of the medical technology company’s stock valued at $76,760,000 after buying an additional 243,610 shares in the last quarter. Epoch Investment Partners Inc. acquired a new stake in CONMED Corporation during the first quarter valued at approximately $9,447,000. Finally, Norges Bank acquired a new stake in CONMED Corporation during the fourth quarter valued at approximately $9,236,000. Institutional investors and hedge funds own 99.77% of the company’s stock.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.